Compare BridgeBio Pharma Inc (BBIO) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? BridgeBio Pharma Inc trades at $83.61 (market cap $16.36B), while ProShares UltraPro Short QQQ ETF trades at $37.03. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | SQQQ | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.17 | $92.95 |
52-Week Low | $47.29 | $36.31 |
Enterprise Value | $18.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $37.15, down 1.56% on the day. Technical indicators are bearish overall, with moving averages signaling selling pressure, though oscillators are neutral. The ETF is designed for short-term tactical use, not long-term holding, due to daily resets that erode value over time.
The outlook for SQQQ is highly speculative, offering potential gains if the Nasdaq-100 declines, but risks are severe, including rapid decay from leverage and volatility decay. It may serve as a hedge for QQQ holdings but is unsuitable as a standalone investment given its long-term performance history of significant losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
